Abstracting and Indexing

  • PubMed NLM
  • Google Scholar
  • Semantic Scholar
  • CrossRef
  • WorldCat
  • ResearchGate
  • Academia.edu
  • Scilit
  • Baidu Scholar
  • DRJI
  • Microsoft Academic
  • Academic Keys
  • Academia.edu
  • OpenAIRE

Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease

Author(s): David S H Bell, Terri Jerkins

A refractory case of abdominal swelling (pseudoascites) due to celiac disease which did not respond to monotherapy with a gluten-free diet and for which treatment with traditional immunosuppressives was refused is described. Based on reports of the anti-inflammatory actions of the GLP-1 receptor agonist, semaglutide, weekly subcutaneous injections of semaglutide were added to the gluten-free diet with rapid and obvious success. Semaglutide and perhaps other GLP-1 receptor agonists should be considered for use as a largely safe anti-inflammatory drug in other autoimmunopathies and inflammatory states.

Journal Statistics

Impact Factor: * 5.8

Acceptance Rate: 71.20%

Time to first decision: 10.4 days

Time from article received to acceptance: 2-3 weeks

Discover More: Recent Articles

Grant Support Articles

© 2016-2025, Copyrights Fortune Journals. All Rights Reserved!